2021
Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line
Strober B, Leman J, Mockenhaupt M, Nakano de Melo J, Nassar A, Prajapati V, Romanelli P, Seneschal J, Tsianakas A, Wei L, Yasuda M, Yu N, Hernandez Daly A, Okubo Y. Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line. Dermatology And Therapy 2021, 12: 381-393. PMID: 34904208, PMCID: PMC8850517, DOI: 10.1007/s13555-021-00661-2.Peer-Reviewed Original ResearchClinical practice gapsPustular psoriasisRobust clinical trial dataPractice gapConsistent treatment guidelinesPathogenesis of GPPGeneralized pustular psoriasisInconsistent diagnostic criteriaCare of patientsHealthcare system levelClinical trial dataAppropriate treatment initiationAutoinflammatory skin diseaseUnmet educational needsSterile pustulesTreatment guidelinesTreatment initiationRecurrent flaresGeneral practitionersAutoinflammatory diseasesDiagnostic criteriaPatientsSkin diseasesMore experienceMultidisciplinary team
2017
Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Herrera V, McLeod L, Odom D, Elewski B. Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. Journal Of Psoriasis And Psoriatic Arthritis 2017, 2: 73-80. DOI: 10.1177/247553031700200206.Peer-Reviewed Original ResearchPsoriasis-related itchingWeek 12Disease severityBenefits of secukinumabInterleukin-17A antagonistSevere plaque psoriasisPatient-reported symptomsClinical trial dataDisease severity scoreQuality of lifeTraditional clinical measuresBackground PsoriasisPASI responseSecukinumab treatmentPlaque psoriasisComplete reliefSymptom reliefSeverity scoreClinical dataResponder statusClinical measuresGreater efficacyTrial dataSecukinumabTreatment effects